EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Lectin‐anticancer peptide fusion demonstrates a significant cancer‐cell‐selective cytotoxic effect and inspires the production of “clickable” anticancer peptide in Escherichia coli

Rajeev Pasupuleti, Sabrina Riedl, Laia Saltor Núñez, Marianna Karava, Vajinder Kumar iD, Robert Kourist, W Bruce Turnbull, Dagmar Zweytick, Birgit Wiltschi iD

Protein Science · 2023

DOI: 10.1002/pro.4830 ↗

At a glance

Journal article in Protein Science, 2023. Written by Rajeev Pasupuleti and 8 co-authors. Institution: acib - Austrian Centre of Industrial Biotechnology, Graz, Austria. Major MEDLINE topics: Antineoplastic Agents, Neoplasms, Dipeptides. Cited 5 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grants, BMK, BMDW, SFG, Standortagentur Tirol, Government of Lower Austria und Vienna Business Agency in the framework of COMET-Competence Centers for Excellent Techno…, Austrian Research Promotion Agency.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Targeted killing of tumor cells while protecting healthy cells is the pressing priority in cancer treatment. Lectins that target a specific glycan marker abundant in cancer cells can be valuable new tools for selective cancer cell killing. The lectin Shiga‐like toxin 1 B subunit (Stx1B) is an example that specifically binds globotriaosylceramide (CD77 or Gb3), which is overexpressed in certain cancers. In this study, a human lactoferricin‐derived synthetic retro di‐peptide R‐DIM‐P‐LF11‐215 with antitumor efficacy was fused to the lectin Stx1B to selectively target and kill Gb3+ cancer cells. We produced lectin‐peptide fusion proteins in Escherichia coli , isolated them by Gb3‐affinity chromatography, and assessed their ability to selectively kill Gb3+ cancer cells in a Calcein AM assay. Furthermore, to expand the applications of R‐DIM‐P‐LF11‐215 in developing therapeutic bioconjugates, we labeled R‐DIM‐P‐LF11‐215 with the unique reactive non‐canonical amino acid N ε ‐((2‐azidoethoxy)carbonyl)‐L‐lysine (AzK) at a selected position by amber stop codon suppression. The R‐DIM‐P‐LF11‐215 20AzK and the unlabeled R‐DIM‐P‐LF11‐215 parent peptide were produced as GST‐fusion proteins for soluble expression in E. coli for the first time. We purified both variants by size‐exclusion chromatography and analyzed their peptide masses. Finally, a cyanin 3 fluorophore was covalently conjugated to R‐DIM‐P‐LF11‐215 20AzK by strain‐promoted alkyne‐azide cycloaddition. Our results showed that the recombinant lectin‐peptide fusion R‐DIM‐P‐LF11‐215‐Stx1B killed >99% Gb3+ HeLa cells while Gb3‐negative cells were unaffected. The peptides R‐DIM‐P‐LF11‐215 and R‐DIM‐P‐LF11‐215 20AzK were produced recombinantly in E. coli in satisfactory amounts and were tested functional by cytotoxicity and cell‐binding assays, respectively.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsNeoplasmsDipeptidesHumansEscherichia coliHeLa CellsLectinsTrihexosylceramides

Author keywords

anticancer peptideclick chemistryfusion proteinshuman lactoferricin-derived peptidepeptide purificationrecombinant peptide productiontargeted drug delivery

Substances

Antineoplastic AgentsLectinsDipeptidesglobotriaosylceramideTrihexosylceramidesR-DIM-P-LF11

Authors and institutions

  • acib - Austrian Centre of Industrial Biotechnology, Graz, Austria.
  • Institute of Molecular Biotechnology, Graz University of Technology, Graz, Austria.
  • Institute of Molecular Biosciences, Biophysics Division, University of Graz, Graz, Austria.
  • BioHealth, University of Graz, Graz, Austria.
  • BioTechMed-Graz, Graz, Austria.
  • School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.

ORCID profiles: Vajinder Kumar, Birgit Wiltschi

Funding

  • European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grants
  • BMK, BMDW, SFG, Standortagentur Tirol, Government of Lower Austria und Vienna Business Agency in the framework of COMET-Competence Centers for Excellent Techno…
  • Austrian Research Promotion Agency
  • University of Natural Resources and Life Sciences Vienna (BOKU)
  • Bundesministerium für Klimaschutz, Umwelt, Energie, Mobilität, Innovation und Technologie
  • Österreichische Forschungsförderungsgesellschaft
  • Universität für Bodenkultur Wien

Cite

APA

Pasupuleti, R., Riedl, S., Saltor Núñez, L., Karava, M., Kumar, V., Kourist, R., Turnbull, W. B., Zweytick, D., & Wiltschi, B. (2023). Lectin‐anticancer peptide fusion demonstrates a significant cancer‐cell‐selective cytotoxic effect and inspires the production of “clickable” anticancer peptide in Escherichia coli. Protein Science. https://doi.org/10.1002/pro.4830

Vancouver

Pasupuleti R, Riedl S, Saltor Núñez L, Karava M, Kumar V, Kourist R, et al. Lectin‐anticancer peptide fusion demonstrates a significant cancer‐cell‐selective cytotoxic effect and inspires the production of “clickable” anticancer peptide in Escherichia coli. Protein Science. 2023. doi:10.1002/pro.4830

BibTeX
@article{Pasupuleti2023,
  author = {Pasupuleti, Rajeev and Riedl, Sabrina and Saltor Núñez, Laia and Karava, Marianna and Kumar, Vajinder and Kourist, Robert and Turnbull, W Bruce and Zweytick, Dagmar and Wiltschi, Birgit},
  title = {Lectin‐anticancer peptide fusion demonstrates a significant cancer‐cell‐selective cytotoxic effect and inspires the production of “clickable” anticancer peptide in Escherichia coli},
  journal = {Protein Science},
  year = {2023},
  doi = {10.1002/pro.4830}
}
Start for free →